Full video transcriptClick to expand
Auto-generated transcript of @drtrevorbachmeyer's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:005-amino-1MQ should be all over the news.
- 0:02Here's its target. Let me explain how it works.
- 0:04It's this diabolical little enzyme called NNMT,
- 0:07nicotinamide n-methyltransferase.
- 0:09That's what it goes after.
- 0:10NNMT is a saboteur of your physiology.
- 0:13Its job is to take two of the most critical raw materials
- 0:18that your body has, nicotinamide,
- 0:19which is a B3 derivative,
- 0:21an esodenazomathione,
- 0:23Sam, your master methyl donor,
- 0:25and set them on fire for like no reason whatsoever.
- 0:28Here's how 5-amino-1MQ works.
- 0:31It walks up to NNMT,
- 0:32and it jams a stick and it spokes,
- 0:35watches it endo down the street.
- 0:36It's a selective inhibitor.
- 0:38When you block NNMT,
- 0:40the biochemical dam breaks.
- 0:42All that nicotinamide that was being wasted
- 0:44now gets funneled directly into something
- 0:46called the salvage pathway.
- 0:47This pathway's only job is to crank out NAD+.
- 0:50Second, you stop the hemorrhaging of Sam,
- 0:53the esodenazomathione,
- 0:55your methylation cycle,
- 0:56the process that controls DNA repair,
- 0:59neurotransmitter synthesis,
- 1:00and detoxification all stabilizes.
- 1:03Here's the main thing, NAD+,
- 1:04NAD+, is the cofactor for life itself.
- 1:06It's the spark plug for every single energy transaction
- 1:10in your body.
- 1:11No NAD+, no energy, period.
- 1:142017 nature was a mic drop.
- 1:16NNMT inhibition in the fat tissue of the obese specifically
- 1:21led to a 47% reduction in fat mass.
- 1:23Let me just repeat that.
- 1:25Nearly half their body fat gone.
- 1:27Meanwhile, listen, meanwhile,
- 1:28their lean mass increased,
- 1:30their energy expenditure skyrocketed,
- 1:32and they eat the same amount of food.
- 1:34They didn't run or work out or do high rocks.
- 1:36The body became a passive fat incinerating machine.
- 1:40Take type two diabetes.
- 1:42It's not a blood sugar problem.
- 1:43It's a cellular deafness problem.
- 1:452018 study and molecular metabolism,
- 1:47they were averse the insulin resistance,
- 1:49no diet, no exercise.
- 1:51They just fixed the broken receiver.
- 1:53Look at cancer.
- 1:54They're metabolic crippled cells.
- 1:57They rely on an inefficient process called the Warburg effect.
- 1:59They ferment glucose for energy,
- 2:01even in the presence of oxygen, glycolysis.
- 2:04They produce lactic acid.
- 2:05Why? Because their mitochondria are broken.
- 2:085-Amina 1MQ forces a metabolic confrontation.
- 2:11You boost NAD+, and restore mitochondrial function
- 2:15in healthy cells, making them stronger.
- 2:17But in cancer cells, with their corrupted pathways,
- 2:20this intervention doesn't help.
- 2:21It triggers the opposite.
- 2:23It causes apoptosis.
- 2:24It's a program cell deaf.
- 2:25So you're giving the good cells a weapon
- 2:28and exposing the bad cells flaw.
- 2:30Look at the worst killers.
- 2:30Glioblastoma, aggressive pancreatic cancer, aggressive.
- 2:34These are monsters and they over-express NNMT.
- 2:37It's a core part of their metabolic strategy.
- 2:392020, nature communications showed NNMT
- 2:42as the key metabolic dependency
- 2:44for pancreatic cancer stem cells,
- 2:46inhibiting it, disrupted the entire tumor's metabolism
- 2:50and crippled its growth.
- 2:51It's ridiculous to think that you're supposed to be sick.
- 2:53You want the research, comment, robust,
- 2:55and I'll give it all to you,
- 2:57including all the stuff you're asking about.
- 2:58Never miss.
5-Amino-1MQ and NNMT inhibition: hype vs. what studies show
Quick answer
5-Amino-1MQ is a small molecule NNMT inhibitor with preclinical data suggesting effects on NAD+ metabolism, adipose tissue remodeling, and insulin sensitivity, all demonstrated in rodent models. No human clinical trial data exists to confirm efficacy, safety, or appropriate dosing for any of the conditions discussed in this video. Patients interested in NAD+ optimization or metabolic support should discuss established, evidence-graded options with a licensed provider before considering unregulated compounds.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For 5-Amino-1MQ and NNMT inhibition: hype vs. what studies show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
5-Amino-1MQ and NNMT inhibition: hype vs. what studies show is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "5-Amino-1MQ and NNMT inhibition: hype vs. what studies show" from Dr Trevor Bachmeyer. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: 5-Amino-1MQ is a small molecule NNMT inhibitor with preclinical data suggesting effects on NAD+ metabolism, adipose tissue remodeling, and insulin sensitivity, all demonstrated in rodent models.
The reason this review is not generic is the source wording and the canonical claim label "peptides 5 amino 1mq should be all over the newscomment robust for re." In this clip, the useful excerpt is: "5-amino-1MQ should be all over the news." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against NAD+ metabolism and its roles in cellular processes during ageing (2021), Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (2021), and Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (2018), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
5-Amino-1MQ is a small molecule NNMT inhibitor with preclinical data suggesting effects on NAD+ metabolism, adipose tissue remodeling, and insulin sensitivity, all demonstrated in rodent models.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- 5-Amino-1MQ is a small molecule NNMT inhibitor with preclinical data suggesting effects on NAD+ metabolism, adipose tissue remodeling, and insulin sensitivity, all demonstrated in rodent models. No human clinical trial data exists to confirm efficacy, safety, or appropriate dosing for any of the conditions discussed in this video. Patients interested in NAD+ optimization or metabolic support should discuss established, evidence-graded options with a licensed provider before considering unregulated compounds.
- Every major study cited in this video, including the 2017 Nature fat mass paper and the 2020 Nature Communications cancer paper, was conducted in mice or cell cultures, not humans.
- NNMT does consume nicotinamide and SAM in a well-characterized enzymatic reaction; the basic biochemistry described is accurate and supported by published literature.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Every major study cited in this video, including the 2017 Nature fat mass paper and the 2020 Nature Communications cancer paper, was conducted in mice or cell cultures, not humans.
- NNMT does consume nicotinamide and SAM in a well-characterized enzymatic reaction; the basic biochemistry described is accurate and supported by published literature.
- 5-Amino-1MQ has no completed human clinical trials as of mid-2025, which means no confirmed safe dose, no established efficacy, and no regulatory quality standards for available products.
- The '47% fat mass reduction' figure comes from Kraus et al. (2014, Nature) in diet-induced obese mice. Applying that number to expected human outcomes is not supported by evidence.
- NNMT overexpression in glioblastoma and pancreatic cancer is a real finding, but framing an unproven compound as a cancer-fighting tool based on cell line data is a significant and potentially harmful leap.
- NAD+ precursor supplements like NMN and NR have more human trial data than 5-amino-1MQ and represent a better-studied entry point for anyone interested in NAD+ optimization.
- If you are metabolically curious about NNMT inhibition, the honest answer from current science is that the mechanism is interesting, the preclinical data warrants further study, and human evidence is not yet available to guide clinical decisions.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drtrevorbachmeyer actually say?
The video argues that an enzyme called NNMT is actively destroying your NAD+ precursors and methyl donors, and that 5-amino-1MQ, a selective NNMT inhibitor, fixes this by rerouting nicotinamide into NAD+ production. The claims escalate quickly. By the end, 5-amino-1MQ is being connected to obesity reversal, insulin resistance, and cancer cell death in glioblastoma and pancreatic tumors.
The specific numbers are bold: "a 47% reduction in fat mass" from a 2017 Nature paper, insulin resistance reversed "no diet, no exercise" from a 2018 Molecular Metabolism study, and NNMT cited as a "key metabolic dependency for pancreatic cancer stem cells" from a 2020 Nature Communications paper. He also says cancer cells "over-express NNMT" and that 5-amino-1MQ triggers "apoptosis" in them specifically. The throughline is that blocking NNMT is a metabolic master key.
Does the science back this up?
Partially, and the gap between what the studies actually showed and what this video implies is significant. The core biochemistry is real. NNMT does consume nicotinamide and SAM, and inhibiting it does increase NAD+ precursor availability. But every study cited was conducted in mice or cell cultures, not humans. That distinction matters enormously.
The 2017 Nature paper (Kraus et al., Nature) did show fat mass reductions in diet-induced obese mice treated with an NNMT inhibitor. The effect was real in that model. The 2018 Molecular Metabolism study (Kannt et al.) also demonstrated improved insulin sensitivity in rodent models. The 2020 Nature Communications paper (Broadfield et al.) on pancreatic cancer stem cells is legitimate research, but it was conducted in cell lines and mouse xenograft models. No clinical trial in humans has demonstrated that 5-amino-1MQ does any of these things in a living person. Saying "nearly half their body fat gone" without specifying this was in mice is a material omission that changes everything.
What did they get wrong (or right)?
They got the mechanism directionally right. NNMT does sit at the intersection of NAD+ metabolism and methylation, and the enzyme is genuinely overexpressed in several cancers and in adipose tissue of obese individuals. That part is textbook biochemistry supported by peer-reviewed literature. Credit where it is due.
What they got wrong is the leap from mouse data to human outcome framing. Describing "47% reduction in fat mass" without the word "mice" is not a minor oversight. It is the kind of framing that leads people to believe a compound has proven human efficacy it simply does not have yet. The cancer section is the most problematic. Saying 5-amino-1MQ "triggers apoptosis" in cancer cells and framing it as "giving good cells a weapon" while "exposing bad cells' flaws" implies a therapeutic effect in humans that no clinical evidence supports. The statement that "type two diabetes is not a blood sugar problem, it's a cellular deafness problem" is reductive to the point of being misleading, though the insulin signaling angle is a real area of research. Calling NAD+ "the cofactor for life itself" is marketing language, not science.
What should you actually know?
5-amino-1MQ is not FDA-approved. It is not a peptide; it is a small molecule compound. It is available through some compounding pharmacies and research chemical suppliers, but it has no completed Phase I, II, or III clinical trial data in humans as of mid-2025. That means no established safety profile, no confirmed effective dose, and no regulatory oversight of quality or purity.
The underlying research is genuinely interesting. NNMT inhibition as a metabolic strategy is being actively studied, and the preclinical data across obesity, metabolic disease, and oncology is promising enough to justify continued investigation. But promising preclinical data has a poor track record of translating into human outcomes, and that history deserves weight. If you are considering 5-amino-1MQ because of content like this, the honest conversation starts with what is not known, not what mice experienced in a controlled lab setting. Talk to a clinician who can review your metabolic labs and assess whether any intervention in this space is appropriate for your situation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dr Trevor Bachmeyer · TikTok creator
33.2K views on this video
5-Amino-1MQ should be all over the newsComment “ROBUST” for research Listen…NNMT is a saboteur #DrTrevorBachmeyer #fitness #gymtok #workoutmotivation #fitnesstips #healthylifestyle #motivationdaily #fittok
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about every major study cited in this video, including the 2017?
Every major study cited in this video, including the 2017 Nature fat mass paper and the 2020 Nature Communications cancer paper, was conducted in mice or cell cultures, not humans.
What does the video say about nnmt does consume nicotinamide?
NNMT does consume nicotinamide and SAM in a well-characterized enzymatic reaction; the basic biochemistry described is accurate and supported by published literature.
What does the video say about 5-amino-1mq has no completed human clinical trials as of mid-2025,?
5-Amino-1MQ has no completed human clinical trials as of mid-2025, which means no confirmed safe dose, no established efficacy, and no regulatory quality standards for available products.
What does the video say about the '47% fat mass reduction' figure comes from kraus et?
The '47% fat mass reduction' figure comes from Kraus et al. (2014, Nature) in diet-induced obese mice. Applying that number to expected human outcomes is not supported by evidence.
What does the video say about nnmt overexpression in glioblastoma?
NNMT overexpression in glioblastoma and pancreatic cancer is a real finding, but framing an unproven compound as a cancer-fighting tool based on cell line data is a significant and potentially harmful leap.
What does the video say about nad+ precursor supplements like nmn?
NAD+ precursor supplements like NMN and NR have more human trial data than 5-amino-1MQ and represent a better-studied entry point for anyone interested in NAD+ optimization.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dr Trevor Bachmeyer, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.